Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Urticaria
Interventions: ARS-1; Drug
Lead sponsor: ARS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Amyloidosis
Interventions: Magnetic Resonance Elastography (MRE); Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pars Interarticularis Stress Fracture, Pars Interarticularis Stress Injury
Interventions: MRI; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 12 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Glucose Control, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Precision Medicine, Nutrition
Interventions: Premeal almond ingestion; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 25 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Erythromelalgia
Interventions: Amitriptyline Hydrochloride, Placebo; Drug
Lead sponsor: AlgoTherapeutix; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Visual Acuity
Interventions: JJVC Investigational Multifocal Contact Lens (senofilcon A c3), Dailies Total 1® Multifocal Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Maitland, Florida • Pittsburg, Florida + 3 more

Conditions: Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions: Suvorexant, Zolpidem, Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: Apremilast Tablet, Apremilast Oral Suspension; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Abrocitinib, Omeprazole, Caffeine, Efavirenz; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Apnea of Prematurity, Hypoxia, Bradycardia
Interventions: Vibration; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 1 Week and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Healthy Volunteers
Interventions: simufilam; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: JNJ-88260237, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Ibrutinib, IMBRUVICA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Squamous Cell Carcinoma, Oropharynx Cancer
Interventions: Intensity modulated radiotherapy (IMRT), PET-MRI; Radiation · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Adults
Interventions: KSP-910638G, 0.4 mg, KSP-910638G, 1.2 mg; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dry Eye Disease
Interventions: 0.003% AR-15512 ophthalmic solution, Artificial tears; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more

Conditions: Acute Mountain Sickness and Fatigue
Interventions: Aminophylline 400 mg, Ambrisentan 5 mg, Placebo; Drug · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Genetic Disease
Interventions: Whole genome sequencing, BeginNGS test, WES; Genetic
Lead sponsor: Rady Pediatric Genomics & Systems Medicine Institute; Other
Eligibility: 1 Day to 10 Days
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Neuroblastoma
Interventions: filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131; Biological · Procedure · Radiation
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more

Conditions: Healthy
Interventions: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: eliglustat; digoxin, digoxin; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer Disease
Interventions: GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions: FloTrac; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy Adult Subjects
Interventions: Omaveloxolone, Efavirenz; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography

Pars Healing on MRI

Eating Almonds Before a Meal to Control Blood Sugar

EASE (Efficacy of ATX01 Study in Erythromelalgia)

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Non-invasive Intervention for Apnea of Prematurity

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

Study of the Safety of KSP Heptapeptide (KSP-910638G)

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

Newborn Genomic Sequencing Pilot Study

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

An Open-label DDI Study of Omaveloxolone in Healthy Subjects